228 related articles for article (PubMed ID: 37353110)
1. β-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer.
Reed ER; Jankowski SA; Spinella AJ; Noonan V; Haddad R; Nomoto K; Matsui J; Bais MV; Varelas X; Kukuruzinska MA; Monti S
Transl Res; 2023 Oct; 260():46-60. PubMed ID: 37353110
[TBL] [Abstract][Full Text] [Related]
2. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
Kartha VK; Alamoud KA; Sadykov K; Nguyen BC; Laroche F; Feng H; Lee J; Pai SI; Varelas X; Egloff AM; Snyder-Cappione JE; Belkina AC; Bais MV; Monti S; Kukuruzinska MA
Genome Med; 2018 Jul; 10(1):54. PubMed ID: 30029671
[TBL] [Abstract][Full Text] [Related]
3. β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma.
Chandler KB; Alamoud KA; Stahl VL; Nguyen BC; Kartha VK; Bais MV; Nomoto K; Owa T; Monti S; Kukuruzinska MA; Costello CE
Mol Omics; 2020 Jun; 16(3):195-209. PubMed ID: 32203567
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
5. RELA promotes the progression of oral squamous cell carcinoma via TFAP2A-Wnt/β-catenin signaling.
Yang K; Zhao J; Liu S; Man S
Mol Carcinog; 2023 May; 62(5):641-651. PubMed ID: 36789977
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal-epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expression.
Horny K; Sproll C; Peiffer L; Furtmann F; Gerhardt P; Gravemeyer J; Stoecklein NH; Spassova I; Becker JC
J Transl Med; 2023 Apr; 21(1):267. PubMed ID: 37076857
[TBL] [Abstract][Full Text] [Related]
7. KDM5B promotes metastasis and epithelial-mesenchymal transition via Wnt/β-catenin pathway in squamous cell carcinoma of the head and neck.
Yuan W; Hu J; Wang M; Li G; Lu S; Qiu Y; Liu C; Liu Y
Mol Carcinog; 2024 May; 63(5):885-896. PubMed ID: 38353298
[TBL] [Abstract][Full Text] [Related]
8. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
9. Chronic restraint stress promotes the tumorigenic potential of oral squamous cell carcinoma cells by reprogramming fatty acid metabolism via CXCL3 mediated Wnt/β-catenin pathway.
Lou F; Long H; Luo S; Liu Y; Pu J; Wang H; Ji P; Jin X
Exp Neurol; 2023 Jan; 359():114268. PubMed ID: 36343679
[TBL] [Abstract][Full Text] [Related]
10. Sex determining region Y-box 9 induced microtubule formation and epithelial⁃mesenchymal transition in human oral squamous cell carcinoma CAL27 cells.
Huang S; Zhang QY; He AE; Li HB; Zhang ZX
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Feb; 39(1):74-80. PubMed ID: 33723940
[TBL] [Abstract][Full Text] [Related]
11. Immunity-related long noncoding RNA WDFY3-AS2 inhibited cell proliferation and metastasis through Wnt/β-catenin signaling in oral squamous cell carcinoma.
Lin X; Ding JM; Zheng XZ; Chen JG
Arch Oral Biol; 2023 Mar; 147():105625. PubMed ID: 36657277
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma.
da Silva SD; Morand GB; Alobaid FA; Hier MP; Mlynarek AM; Alaoui-Jamali MA; Kowalski LP
Clin Exp Metastasis; 2015 Jan; 32(1):55-63. PubMed ID: 25433796
[TBL] [Abstract][Full Text] [Related]
13. Immunoexpression of Epithelial Mesenchymal Transition Proteins E-Cadherin, β-Catenin, and N-Cadherin in Oral Squamous Cell Carcinoma.
Angadi PV; Patil PV; Angadi V; Mane D; Shekar S; Hallikerimath S; Kale AD; Kardesai SG
Int J Surg Pathol; 2016 Dec; 24(8):696-703. PubMed ID: 27312520
[TBL] [Abstract][Full Text] [Related]
14. SNHG17/miR-384/ELF1 axis promotes cell growth by transcriptional regulation of CTNNB1 to activate Wnt/β-catenin pathway in oral squamous cell carcinoma.
Qiao C; Qiao T; Yang S; Liu L; Zheng M
Cancer Gene Ther; 2022 Jan; 29(1):122-132. PubMed ID: 33531646
[TBL] [Abstract][Full Text] [Related]
15. CLSPN actives Wnt/β-catenin signaling to facilitate glycolysis and cell proliferation in oral squamous cell carcinoma.
Hou Z; Wu C; Tang J; Liu S; Li L
Exp Cell Res; 2024 Feb; 435(2):113935. PubMed ID: 38237848
[TBL] [Abstract][Full Text] [Related]
16. Casticin inhibits invasion and proliferation via downregulation of β-catenin and reversion of EMT in oral squamous cell carcinoma.
Xie Y; Zhong L; Duan D; Li T
J Oral Pathol Med; 2019 Nov; 48(10):897-905. PubMed ID: 31318467
[TBL] [Abstract][Full Text] [Related]
17. Isoorientin inhibits epithelial-to-mesenchymal properties and cancer stem-cell-like features in oral squamous cell carcinoma by blocking Wnt/β-catenin/STAT3 axis.
Liu SC; Huang CS; Huang CM; Hsieh MS; Huang MS; Fong IH; Yeh CT; Lin CC
Toxicol Appl Pharmacol; 2021 Aug; 424():115581. PubMed ID: 34019859
[TBL] [Abstract][Full Text] [Related]
18. CD147 promotes proliferation and migration of oral cancer cells by inhibiting junctions between E-cadherin and β-catenin.
Min A; Xiong H; Wang W; Hu X; Wang C; Mao T; Yang L; Huang D; Xia K; Su T
J Oral Pathol Med; 2020 Nov; 49(10):1019-1029. PubMed ID: 32740991
[TBL] [Abstract][Full Text] [Related]
19. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
20. CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway.
Li Y; Liu C; Zhang X; Huang X; Liang S; Xing F; Tian H
Br J Cancer; 2022 Jun; 126(12):1684-1694. PubMed ID: 35194191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
